117 related articles for article (PubMed ID: 38183682)
1. Development of new thieno[2,3-d]pyrimidines as dual EGFR and STAT3 inhibitors endowed with anticancer and pro-apoptotic activities.
Elsebaie HA; El-Moselhy TF; El-Bastawissy EA; Elberembally KM; Badi RM; Elkaeed EB; Shaldam MA; Eldehna WM; Tawfik HO
Bioorg Chem; 2024 Feb; 143():107101. PubMed ID: 38183682
[TBL] [Abstract][Full Text] [Related]
2. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
3. Discovery of new thieno[2,3-
Sobh EA; Dahab MA; Elkaeed EB; Alsfouk AA; Ibrahim IM; Metwaly AM; Eissa IH
Future Med Chem; 2023 Jul; 15(13):1167-1184. PubMed ID: 37529910
[No Abstract] [Full Text] [Related]
4. New C2- and N3-Modified Thieno[2,3-d]Pyrimidine Conjugates with Cytotoxicity in the Nanomolar Range.
Mavrova AT; Dimov S; Yancheva D; Rangelov M; Wesselinova D; Naydenova E
Anticancer Agents Med Chem; 2022; 22(6):1201-1212. PubMed ID: 34315388
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
6. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity.
Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA
Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427
[TBL] [Abstract][Full Text] [Related]
8. Computer aided drug discovery (CADD) of a thieno[2,3-
Sobh EA; Dahab MA; Elkaeed EB; Alsfouk AA; Ibrahim IM; Metwaly AM; Eissa IH
J Biomol Struct Dyn; 2024 Mar; 42(5):2369-2391. PubMed ID: 37129193
[TBL] [Abstract][Full Text] [Related]
9. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
[TBL] [Abstract][Full Text] [Related]
10. Novel 4-(2-arylidenehydrazineyl)thienopyrimidine derivatives as anticancer EGFR inhibitors: Design, synthesis, biological evaluation, kinome selectivity and in silico insights.
Elsebaie HA; El-Bastawissy EA; Elberembally KM; Khaleel EF; Badi RM; Shaldam MA; Eldehna WM; Tawfik HO; El-Moselhy TF
Bioorg Chem; 2023 Nov; 140():106799. PubMed ID: 37625210
[TBL] [Abstract][Full Text] [Related]
11. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, docking, MD simulations, and anti-proliferative evaluation of thieno[2,3-
Sobh EA; Dahab MA; Elkaeed EB; Alsfouk AA; Ibrahim IM; Metwaly AM; Eissa IH
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2220579. PubMed ID: 37288786
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
15. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3-d]pyrimidine derivatives as EGFR inhibitors.
Sayed MTM; Halim PA; El-Ansary AK; Hassan RA
Drug Dev Res; 2023 Sep; 84(6):1299-1319. PubMed ID: 37357422
[TBL] [Abstract][Full Text] [Related]
17. Development of Novel Class of Phenylpyrazolo[3,4-
Aljohani AKB; El Zaloa WAZ; Alswah M; Seleem MA; Elsebaei MM; Bayoumi AH; El-Morsy AM; Almaghrabi M; Awaji AA; Hammad A; Alsulaimany M; Ahmed HEA
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834474
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors.
Zhang D; Yan Y; Jin G; Liu B; Ma X; Han D; Jia X
Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800110. PubMed ID: 30048007
[TBL] [Abstract][Full Text] [Related]
19. Benzimidazole-linked pyrazolo[1,5-a]pyrimidine conjugates: synthesis and detail evaluation as potential anticancer agents.
Bagul C; Rao GK; Veena I; Kulkarni R; Tamboli JR; Akunuri R; Shaik SP; Pal-Bhadra M; Kamal A
Mol Divers; 2023 Jun; 27(3):1185-1202. PubMed ID: 36114912
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
